Teprotumumab Improves the Clinical Course of Thyroid Eye Disease Across Multiple Subgroups of Patients with Durable Responses

xlomafota13 shared this article with you from Inoreader Teprotumumab Improves the Clinical Course of Thyroid Eye Disease Across Multiple Subgroups of Patients with Durable Responses Via Clinical Thyroidology Clinical Thyroidology, Volume 33, Issue 7, Page 312-315, July 2021. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.